Teva Pharmaceutical Industries (NYSE:TEVA) Agrees To Pay Over $519 Million To Settle Parallel Civil And Criminal Charges

Teva Pharmaceutical Industries (NYSE:TEVA) runs in leading trade, it Dropping -1.30% to traded at $36.34. TEVA attains analyst recommendation of 2.10 on scale of 1-5 with week’s performance of 0.85%. The U.S. Securities and Exchange Commission (SEC) reported that Teva Pharmaceutical Industries Ltd. (TEVA) has agreed to pay over $519 million to settle parallel civil and criminal charges that it violated the Foreign Corrupt Practices Act (FCPA) by paying bribes to foreign government officials in Russia, Ukraine, and Mexico.

According to the SEC’s complaint, Teva allegedly made more than $214 million in illicit profits by making the influential payments to increase its market share and obtain regulatory and formulary approvals as well as favorable drug purchase and prescription decisions in the aforementioned countries.

To find out the technical position of TEVA, it holds price to book ratio of 1.14 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 6.76, and price to earnings ratio calculated as 21.27. The price to earnings growth ration calculated as 9.99. TEVA is presenting price to cash flow of 24.04.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -48.90%, and looking further price to next year’s EPS is 6.18%. While take a short look on price to sales ratio, that was 1.86 and price to earning ration of 21.27 attracting passive investors.

Organovo Holdings, Inc. (NASDAQ:ONVO) kept active in under and overvalue discussion, ONVO holds price to book ratio of 6.66 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation. .

Fundament/ News Factor in Focus

The co is presenting price to cash flow as 7.19, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 4.61% for a week and 6.51% for a month. Its beta stands at 1.53 times. Narrow down four to firm performance, its weekly performance was -0.27% and monthly performance was 14.42%.


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *